SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

HAVING DISCUSSED IMPORTANT lymphoma and chronic lymphocytic leukemia abstracts from the 66th American Society of Hematology ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

A panelist discusses how identifying steroid-dependent or steroid-refractory (SR) graft-vs-host disease (GVHD) requires careful clinical monitoring, with the determination typically made when patients ...

The DecisionDx-Melanoma test accurately identifies low sentinel lymph node risk in melanoma, according to the DECIDE study.

Nicolas Ferreyros discussed central ideas from the Community Oncology Alliance to optimize cancer care in community oncology ...

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.